168 related articles for article (PubMed ID: 28766969)
1. Meta-analysis of clinical significance of p53 protein expression in patients with osteosarcoma.
Wu J; Guo A; Li Q; Wang D
Future Oncol; 2017 Sep; 13(21):1883-1891. PubMed ID: 28766969
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of p53 alterations in human osteosarcoma: a meta analysis.
Yao D; Cai GH; Chen J; Ling R; Wu SX; Li YP
Int J Clin Exp Pathol; 2014; 7(10):6725-33. PubMed ID: 25400752
[TBL] [Abstract][Full Text] [Related]
3. Effects of vascular endothelial growth factor expression on pathological characteristics and prognosis of osteosarcoma.
Han G; Wang Y; Bi W; Jia J; Wang W; Xu M
Clin Exp Med; 2016 Nov; 16(4):577-584. PubMed ID: 26319790
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of tumor suppressors in osteosarcoma before and after neoadjuvant chemotherapy.
Robl B; Pauli C; Botter SM; Bode-Lesniewska B; Fuchs B
BMC Cancer; 2015 May; 15():379. PubMed ID: 25956431
[TBL] [Abstract][Full Text] [Related]
5. [The effect of resistance-related proteins on the prognosis and survival of patients with osteosarcoma: an immunohistochemical analysis].
Ozger H; Eralp L; Atalar AC; Toker B; Esberk Ateş L; Sungur M; Bilgiç B; Ayan I
Acta Orthop Traumatol Turc; 2009; 43(1):28-34. PubMed ID: 19293613
[TBL] [Abstract][Full Text] [Related]
6. P16 protein expression as a useful predictive biomarker for neoadjuvant chemotherapy response in patients with high-grade osteosarcoma: A systematic meta-analysis under guideline of PRISMA.
Tang Y; Yang C; Guo Z; Fu Y; Yu X; Liu B; Zhou H; Wang J; Li W; Pang Q
Medicine (Baltimore); 2017 May; 96(19):e6714. PubMed ID: 28489748
[TBL] [Abstract][Full Text] [Related]
7. A systematic review of p53 as a biomarker of survival in patients with osteosarcoma.
Fu HL; Shao L; Wang Q; Jia T; Li M; Yang DP
Tumour Biol; 2013 Dec; 34(6):3817-21. PubMed ID: 24014053
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of P-glycoprotein, HER-2/ErbB-2, p53, and Bcl-2 in primary tumor and metachronous lung metastases in patients with high-grade osteosarcoma.
Ferrari S; Bertoni F; Zanella L; Setola E; Bacchini P; Alberghini M; Versari M; Bacci G
Cancer; 2004 May; 100(9):1936-42. PubMed ID: 15112275
[TBL] [Abstract][Full Text] [Related]
9. Analysis of HSP27 and the Autophagy Marker LC3B
Livingston JA; Wang WL; Tsai JW; Lazar AJ; Leung CH; Lin H; Advani S; Daw N; Santiago-O'Farrill J; Hollomon M; Gordon NB; Kleinerman ES
Mol Cancer Ther; 2018 Jun; 17(6):1315-1323. PubMed ID: 29592877
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of bax, bcl-2, and p53 staining in primary osteosarcoma.
Kaseta MK; Khaldi L; Gomatos IP; Tzagarakis GP; Alevizos L; Leandros E; Papagelopoulos PJ; Soucacos PN
J Surg Oncol; 2008 Mar; 97(3):259-66. PubMed ID: 18161867
[TBL] [Abstract][Full Text] [Related]
11. Elevated expression of microRNA-19a predicts a poor prognosis in patients with osteosarcoma.
Zou P; Ding J; Fu S
Pathol Res Pract; 2017 Mar; 213(3):194-198. PubMed ID: 28214202
[TBL] [Abstract][Full Text] [Related]
12. Expression of CD133 protein in osteosarcoma and its relationship with the clinicopathological features and prognosis.
Xie Y; Huang J; Wu M; Zhou Y
J Cancer Res Ther; 2018; 14(4):892-895. PubMed ID: 29970672
[TBL] [Abstract][Full Text] [Related]
13. Tissue microRNA-126 expression level predicts outcome in human osteosarcoma.
Liu W; Zhao ZY; Shi L; Yuan WD
Diagn Pathol; 2015 Jul; 10():116. PubMed ID: 26194657
[TBL] [Abstract][Full Text] [Related]
14. Expression of HER2/erbB-2 correlates with survival in osteosarcoma.
Gorlick R; Huvos AG; Heller G; Aledo A; Beardsley GP; Healey JH; Meyers PA
J Clin Oncol; 1999 Sep; 17(9):2781-8. PubMed ID: 10561353
[TBL] [Abstract][Full Text] [Related]
15. Prognostic impact of blood and urinary angiogenic factor levels at diagnosis and during treatment in patients with osteosarcoma: a prospective study.
Tabone MD; Brugières L; Piperno-Neumann S; Selva MA; Marec-Bérard P; Pacquement H; Lervat C; Corradini N; Gentet JC; Couderc R; Chevance A; Mahier-Ait Oukhatar C; Entz-Werle N; Blay JY; Le Deley MC
BMC Cancer; 2017 Jun; 17(1):419. PubMed ID: 28619014
[TBL] [Abstract][Full Text] [Related]
16. The co-expression of p53 protein and P-glycoprotein is correlated to a poor prognosis in osteosarcoma.
Park YB; Kim HS; Oh JH; Lee SH
Int Orthop; 2001; 24(6):307-10. PubMed ID: 11294418
[TBL] [Abstract][Full Text] [Related]
17. RANKL expression is related to treatment outcome of patients with localized, high-grade osteosarcoma.
Lee JA; Jung JS; Kim DH; Lim JS; Kim MS; Kong CB; Song WS; Cho WH; Jeon DG; Lee SY; Koh JS
Pediatr Blood Cancer; 2011 May; 56(5):738-43. PubMed ID: 21370405
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Significance of Survivin Expression in Osteosarcoma Patients: A Meta-Analysis.
Liu Y; Teng Z; Wang Y; Gao P; Chen J
Med Sci Monit; 2015 Sep; 21():2877-85. PubMed ID: 26408642
[TBL] [Abstract][Full Text] [Related]
19. Expression of Leptin and Sirtuin-1 is associated with poor prognosis in patients with osteosarcoma.
Feng H; Guo P; Wang J; Xu J; Xie C; Gao F
Pathol Res Pract; 2016 Apr; 212(4):319-24. PubMed ID: 26936024
[TBL] [Abstract][Full Text] [Related]
20. The role of vascular endothelial growth factor as a prognostic and clinicopathological marker in osteosarcoma: a systematic review and meta-analysis.
Zhang C; Wang L; Xiong C; Zhao R; Liang H; Luo X
J Orthop Surg Res; 2021 Dec; 16(1):738. PubMed ID: 34963495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
